

Appendix 1
Supplementary Table 1 – Comparison of CDI severity between subgroups of interest

	CDI severity		p value
	Mild to moderate (n = 310)	Severe (with or without complications) (n = 141)	
Sex, n (%)			
Male	143 (46.1%)	58 (41.1%)	0.2905
Female	167 (53.9%)	83 (58.9%)	
Age group*, n (%)			
18-64	79 (25.5%)	11 (7.8%)	0.0001
≥65	231 (74.5%)	130 (92.2%)	
≥1 Comorbidity of interest*, n (%)			
Yes	279 (90.0%)	130 (92.2%)	0.5037
No	31 (10.0%)	11 (7.8%)	
Antibiotic use in the last 3 months, n (%)**			
Yes	264 (85.7%)	122 (86.5%)	0.9761
No	44 (14.3%)	19 (13.5%)	
Continuous PPI treatment, n (%)			
Yes	159 (51.3%)	69 (48.9%)	0.7530
No	151 (48.7%)	72 (51.1%)	
On hemodialysis, n (%)**			
Yes	37 (12.0%)	14 (9.9%)	0.6959
No	272 (88.0%)	127 (90.1%)	
Immunosuppression, n (%)			
Yes	91 (29.4%)	44 (31.2%)	0.7517
No	219 (70.6%)	97 (68.8%)	

CDI, *Clostridioides difficile* infection; PPI, proton pump inhibitor

*At the time of the first primary CDI episode diagnosed in 2017.

**Percentages determined based on non-missing values.

Supplementary Table 2 – Comparison of time to recurrence between subgroups of interest

	Time to recurrence (days)			p value
	N	Mean (SD)	Median (Minimum-Maximum)	
Sex				
Male	30	29.97 (9.28)	28.00 (17.00-53.00)	0.8267
Female	30	28.83 (9.10)	29.50 (14.00-50.00)	
Age group*				
18-64 years	12	23.75 (7.92)	22.00 (14.00-40.00)	0.0012
≥65 years	48	30.81 (8.93)	29.50 (17.00-53.00)	
≥1 Comorbidity of interest*				
Yes	55	29.33 (8.73)	28.00 (14.00-53.00)	0.9921
No	5	30.20 (14.13)	26.00 (15.00-47.00)	
Antibiotic use in the last 3 months				
Yes	58	29.48 (9.26)	28.00 (14.00-53.00)	0.3012
No	2	27.00 (4.24)	27.00 (24.00-30.00)	
On hemodialysis				
Yes	5	27.20 (5.26)	28.00 (21.00-34.00)	0.4968
No	55	29.60 (9.41)	28.00 (14.00-53.00)	
Immunosuppression				
Yes	17	28.59 (7.91)	28.00 (14.00-45.00)	0.5102
No	43	29.72 (9.64)	28.00 (15.00-53.00)	
Continuous PPI treatment				
Yes	32	31.50 (8.74)	30.00 (17.00-53.00)	0.0644
No	28	27.00 (9.12)	24.50 (14.00-46.00)	

PPI, proton pump inhibitor

*At the time of the first primary CDI episode diagnosed in 2017.

Supplementary Table 3 – Ribotype distribution among toxigenic strains and resistance to moxifloxacin (national surveillance data)

Ribotype, n (%)	Toxigenic strains* (n=187)	Toxigenic strains positive for binary toxin (n=35)	Moxifloxacin resistance (n=39)***
RT027	16 (8.6%)	16 (45.7%)	16 (43.2%)
RT078/126	16 (8.6%)	16 (45.7%)	8 (21.6%)
RT14	15 (8.0%)		2 (5.4%)
RT106	14 (7.5%)		5 (13.5%)
RT002	11 (5.9%)		
RT020	10 (5.3%)		
RT001	6 (3.2%)		
RT003	4 (2.1%)		1 (2.7%)
RT005	8 (4.3%)		
RT012	3 (1.6%)		
RT013	3 (1.6%)		
RT015	6 (3.2%)		
RT017**	3 (1.6%)		3 (8.1%)
RT023	3 (1.6%)	3 (8.6%)	
RT026	1 (0.5%)		
RT029	1 (0.5%)		
RT043	3 (1.6%)		
RT046	1 (0.5%)		
RT049	3 (1.6%)		
RT050	2 (1.1%)		
RT056	6 (3.2%)		
RT076	3 (1.6%)		
RT081	3 (1.6%)		
RT087	3 (1.6%)		
RT103	1 (0.5%)		

RT149	1 (0.5%)	
RT154	1 (0.5%)	
RT163	2 (1.1%)	
RT200	1 (0.5%)	
RT235	2 (1.1%)	
RT241	2 (1.1%)	1 (2.7%)
RT295	3 (1.6%)	
RT328	1 (0.5%)	
RT430	1 (0.5%)	
RT434	1 (0.5%)	
RT449	2 (1.1%)	
RT464	2 (1.1%)	
RT481	1 (0.5%)	
RT534	1 (0.5%)	
RT538	1 (0.5%)	
RT565	1 (0.5%)	
RT572	1 (0.5%)	
RT598	1 (0.5%)	
RT614	3 (1.6%)	
RT616	1 (0.5%)	
RT651	8 (4.3%)	
RT715	1 (0.5%)	
Unknown	4 (2.1%)	1 (2.7%)

*Positive for toxins A and/or B

**Positive for toxin B only

***Two moxifloxacin strains are non-toxigenic. Percentages were determined for the total of moxifloxacin toxigenic strains (n=37)